Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant
NCT01627275 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28
Last updated 2018-02-13
Summary
Allogeneic stem cell transplantation offers the hope of cure for a wide variety of hematologic malignancies. Mature donor T-cells play a critical role in the success or failure of this procedure and a subset of donor T-cells mediate graft-versus-host disease while other subsets provide the foundation for immune recovery. The major challenge in allogeneic stem cell transplantation is determining how to maximally exploit the beneficial effects mediated by T-cells without causing GvHD. This challenge could be overcome by selectively depleting the population of donor T-cells responsible for eliciting the GvHD response. The study hypothesis is depletion of naïve T-cells from the donor lymphocyte inoculum will not cause GVHD while providing T-cells to affect both anti-infection and anti-tumor responses.
Conditions
Interventions
- BIOLOGICAL
-
Naive T Cell Depleted Donor Lymphocyte Infusion
A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
Sponsors & Collaborators
-
Mitchell Horwitz, MD
lead OTHER
Principal Investigators
-
Mitchell Horwitz, MD · Duke University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2017-02-24
- Completion
- 2017-08-03
Countries
- United States
Study Locations
More Related Trials
-
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
NCT01050764 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
NCT00143559 ·Status: COMPLETED ·Phase: PHASE2
-
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
NCT01087294 ·Status: COMPLETED ·Phase: PHASE1
-
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
NCT00080925 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
NCT00984165 ·Status: TERMINATED ·Phase: PHASE2
-
Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant
NCT00476177 ·Status: COMPLETED ·Phase: PHASE1
-
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
NCT01523223 ·Status: COMPLETED ·Phase: PHASE1
-
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
NCT00025662 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
NCT00674427 ·Status: TERMINATED ·Phase: PHASE1
-
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
NCT01497184 ·Status: COMPLETED ·Phase: PHASE1
-
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
NCT01341301 ·Status: COMPLETED ·Phase: PHASE2
-
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
NCT04464889 ·Status: WITHDRAWN ·Phase: PHASE1
-
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01871441 ·Status: TERMINATED ·Phase: PHASE2
-
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
NCT00104975 ·Status: COMPLETED ·Phase: PHASE1
-
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
NCT07285668 ·Status: SUSPENDED ·Phase: NA
-
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
NCT00597714 ·Status: COMPLETED ·Phase: PHASE2
-
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
NCT00038779 ·Status: TERMINATED ·Phase: NA
-
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
NCT00003196 ·Status: COMPLETED ·Phase: NA
-
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
NCT02566395 ·Status: COMPLETED ·Phase: PHASE3
-
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
NCT01384513 ·Status: COMPLETED ·Phase: PHASE2
-
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
NCT00368355 ·Status: COMPLETED ·Phase: PHASE2
-
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
NCT00374933 ·Status: COMPLETED ·Phase: PHASE1
-
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00683046 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic Transplantation From Related Haploidentical Donors
NCT00185692 ·Status: COMPLETED ·Phase: PHASE2
-
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
NCT01621477 ·Status: TERMINATED ·Phase: PHASE2